JPWO2019217643A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217643A5 JPWO2019217643A5 JP2020562156A JP2020562156A JPWO2019217643A5 JP WO2019217643 A5 JPWO2019217643 A5 JP WO2019217643A5 JP 2020562156 A JP2020562156 A JP 2020562156A JP 2020562156 A JP2020562156 A JP 2020562156A JP WO2019217643 A5 JPWO2019217643 A5 JP WO2019217643A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- acceptable salt
- hcv
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 30
- 241000711549 Hepacivirus C Species 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 20
- 229960002063 sofosbuvir Drugs 0.000 claims 9
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical group N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims 9
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 8
- 229960000863 velpatasvir Drugs 0.000 claims 8
- FHCUMDQMBHQXKK-CDIODLITSA-N velpatasvir Chemical group C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](C[C@@H](C2)COC)C=2NC(=CN=2)C=2C=C3C(C4=CC5=CC=C6NC(=NC6=C5C=C4OC3)[C@H]3N([C@@H](C)CC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)=CC=CC=C1 FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 claims 8
- 229940126062 Compound A Drugs 0.000 claims 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 6
- VJYSBPDEJWLKKJ-NLIMODCCSA-N methyl n-[(2s,3r)-1-[(2s)-2-[6-[(2r,5r)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2s)-1-[(2s,3r)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3h-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1h-benzimidazol-2 Chemical compound COC(=O)N[C@@H]([C@@H](C)OC)C(=O)N1CCC[C@H]1C1=NC2=CC(F)=C([C@@H]3N([C@H](CC3)C=3C(=CC=4N=C(NC=4C=3)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)F)C=3C=C(F)C(N4CCC(CC4)C=4C=CC(F)=CC=4)=C(F)C=3)C=C2N1 VJYSBPDEJWLKKJ-NLIMODCCSA-N 0.000 claims 5
- 229950007513 pibrentasvir Drugs 0.000 claims 5
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 4
- 229960005449 daclatasvir Drugs 0.000 claims 4
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims 4
- 229940000425 combination drug Drugs 0.000 claims 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- -1 elvasville Chemical compound 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 claims 2
- 229960002461 ledipasvir Drugs 0.000 claims 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 2
- 229960000518 ombitasvir Drugs 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 229960002118 asunaprevir Drugs 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- ZTTKEBYSXUCBSE-QDFUAKMASA-N beclabuvir Chemical compound C1([C@@H]2C[C@@]2(CN2C3=CC(=CC=C33)C(=O)NS(=O)(=O)N(C)C)C(=O)N4[C@@H]5CC[C@H]4CN(C)C5)=CC(OC)=CC=C1C2=C3C1CCCCC1 ZTTKEBYSXUCBSE-QDFUAKMASA-N 0.000 claims 1
- 229950010541 beclabuvir Drugs 0.000 claims 1
- MUICUPWICXUNRS-GDCCIXDYSA-N chembl3121539 Chemical compound C1CC(C)=CC[C@@H]1C(=O)N(C1=C(SC(=C1)C#CC(C)(C)C)C(O)=O)[C@@H]1CC[C@@](O)(CO[C@@H]2COCC2)CC1 MUICUPWICXUNRS-GDCCIXDYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960001418 dasabuvir Drugs 0.000 claims 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 claims 1
- 229960002754 paritaprevir Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 1
- 229950008104 radalbuvir Drugs 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960002091 simeprevir Drugs 0.000 claims 1
- JTZZSQYMACOLNN-VDWJNHBNSA-N simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 claims 1
- 229940118849 sofosbuvir and ledipasvir Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669007P | 2018-05-09 | 2018-05-09 | |
| US62/669,007 | 2018-05-09 | ||
| PCT/US2019/031459 WO2019217643A1 (en) | 2018-05-09 | 2019-05-09 | Combination therapy for treatment of hcv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523129A JP2021523129A (ja) | 2021-09-02 |
| JPWO2019217643A5 true JPWO2019217643A5 (enExample) | 2022-05-17 |
| JP7381493B2 JP7381493B2 (ja) | 2023-11-15 |
Family
ID=66641500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562156A Active JP7381493B2 (ja) | 2018-05-09 | 2019-05-09 | Ｈｃｖを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11752166B2 (enExample) |
| EP (1) | EP3790542B1 (enExample) |
| JP (1) | JP7381493B2 (enExample) |
| KR (1) | KR20210018806A (enExample) |
| CN (1) | CN112203652A (enExample) |
| AU (1) | AU2019265740A1 (enExample) |
| CA (1) | CA3096916A1 (enExample) |
| MX (1) | MX2020011912A (enExample) |
| TW (1) | TWI833753B (enExample) |
| WO (1) | WO2019217643A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230285435A1 (en) * | 2020-07-17 | 2023-09-14 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
| JP2024525164A (ja) | 2021-06-17 | 2024-07-10 | アテア ファーマシューティカルズ， インコーポレイテッド | 有利な抗ｈｃｖ併用療法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| BR0210357A (pt) | 2001-06-11 | 2004-06-29 | Shire Biochem Inc | Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus |
| US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| DE60332482D1 (de) | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| AU2003291886A1 (en) | 2002-12-10 | 2004-06-30 | Virochem Pharma Inc. | Thiophenederivatives for the treatment of flavivirus infections |
| JP4926403B2 (ja) | 2002-12-10 | 2012-05-09 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染の処置もしくは予防のための化合物および方法 |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| MX2007014117A (es) | 2005-05-13 | 2008-02-05 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones de flavivirus. |
| WO2008017688A1 (en) | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
| WO2008043791A2 (en) | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
| AP2579A (en) | 2006-11-15 | 2013-01-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| JP2010510191A (ja) | 2006-11-17 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス剤としての２−カルボキシチオフェン誘導体 |
| GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
| GB0712393D0 (en) | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
| BR112015009636A8 (pt) * | 2012-10-29 | 2018-04-17 | Cocrystal Pharma Inc | composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto |
| JP2017513852A (ja) * | 2014-04-15 | 2017-06-01 | コクリスタル ファーマ，インコーポレイテッド | Ｃ型肝炎ウイルスの強力及び選択的な阻害剤 |
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| US9937160B2 (en) * | 2015-07-16 | 2018-04-10 | Cipla (UK) Limited | Thienopyridine derivative for the treatment of hepatitis C infections |
-
2019
- 2019-05-09 CN CN201980030086.3A patent/CN112203652A/zh active Pending
- 2019-05-09 US US17/047,209 patent/US11752166B2/en active Active
- 2019-05-09 WO PCT/US2019/031459 patent/WO2019217643A1/en not_active Ceased
- 2019-05-09 JP JP2020562156A patent/JP7381493B2/ja active Active
- 2019-05-09 TW TW108116038A patent/TWI833753B/zh active
- 2019-05-09 EP EP19726259.5A patent/EP3790542B1/en active Active
- 2019-05-09 MX MX2020011912A patent/MX2020011912A/es unknown
- 2019-05-09 KR KR1020207033655A patent/KR20210018806A/ko not_active Ceased
- 2019-05-09 AU AU2019265740A patent/AU2019265740A1/en not_active Abandoned
- 2019-05-09 CA CA3096916A patent/CA3096916A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2008518943A5 (enExample) | ||
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
| JP2004509061A5 (enExample) | ||
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| JP2005524632A5 (enExample) | ||
| JP2007504260A5 (enExample) | ||
| WO1995003056A1 (en) | Hepatitis c virus proliferation inhibitor | |
| JP2002515453A5 (enExample) | ||
| JP2010505902A5 (enExample) | ||
| HK1255463A1 (zh) | Hbv衣壳组装抑制剂和干扰素的组合疗法 | |
| JP2013529627A5 (enExample) | ||
| JP2005516041A5 (enExample) | ||
| JP2019505553A5 (enExample) | ||
| JP2009510129A5 (enExample) | ||
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| JPWO2019200005A5 (enExample) | ||
| JPWO2019217643A5 (enExample) | ||
| JP2011524359A5 (enExample) | ||
| JPWO1999018993A1 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| RU2009104066A (ru) | Профилактический или терапевтический агент против вирусного заболевания | |
| Marcellin et al. | 95 Peginterferon alfa-2A (40KD)(PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine | |
| Lampertico et al. | P135 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301 | |
| Scotto et al. | Treatment with ribavirin+ alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results | |
| JPWO2019217369A5 (enExample) |